| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Bacterial cell membranes (Gram-positive bacteria) and fungal cell membranes. Nisin Z exerts its antimicrobial effect by forming pores in the membrane, leading to cell death. It also has anti-inflammatory activity by reducing pro-inflammatory cytokine production.
|
|---|---|
| ln Vitro |
Gingival fibroblasts are more likely to detach and differentiate when exposed to Nisin Z (10 μg/mL, 24 h) [2]. For 24 hours, nisin Z (25–75 μg/mL) prevents C from adhering. gingival cells to albicans[2]. Nisin Z (500 and 1000 μg/mL, 24 hours) prevents C from forming germ tubes. albicans [3]. Nisin Z (10-100 μg/mL, 12 h) inhibits LPS-induced activation of ERK1/2 and p38 MAPK signaling pathways in MCF10A cells [4]. Nisin Z (100 μg/mL, 12 h) lowers LPS-induced production of pro-inflammatory cytokines (i.e., IL-6, TNF-α, IL-1β) in MCF10A cells [4].
Nisin Z (10 µg/mL, 24 hours) increases gingival fibroblast detachment and differentiation. At 25-75 µg/mL, it exhibits antimicrobial activity against various Gram-positive bacteria and fungi. Detailed MIC values against specific pathogens are available from specialized databases. |
| ln Vivo |
In an LPS-induced mouse mastitis model, nisin Z (1, 5 and 10 mg/kg, ip) inhibits pathological damage [4].
In vivo activity data for Nisin Z is not extensively detailed in standard references. As an antimicrobial peptide, it is expected to show efficacy in animal models of bacterial and fungal infections. It is used in food preservation research, suggesting it is safe for topical or oral applications. |
| Enzyme Assay |
In vitro antimicrobial susceptibility testing is performed using standard broth microdilution methods (CLSI guidelines). The compound is serially diluted in 96-well plates, and bacterial or fungal cultures are added. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible growth.
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: C. albicans Tested Concentrations: 100, 500, 1000 μg/mL Incubation Duration: 24, 48, and 72 h Experimental Results: decreased C. albicans growth. Western Blot Analysis[4] Cell Types: LPS-induced MCF10A cells Tested Concentrations: 10-100 μg/mL Incubation Duration: 12 h Experimental Results: Inhibited the phosphorylation of p38 and and ERK1/ 2. In vitro cell-based assays for anti-inflammatory activity are performed using LPS-stimulated macrophages. Cells are treated with Nisin Z, and pro-inflammatory cytokine levels (e.g., TNF-α, IL-6) in the culture supernatant are measured by ELISA. Cell viability is assessed using MTT assays to exclude cytotoxicity. |
| Animal Protocol |
Animal/Disease Models: Mastitis mouse model[4]
Doses: 1, 5, and 10 mg/kg Route of Administration: ip, one hour before treatment of LPS. Experimental Results: diminished inflammatory cell infiltration. demonstrated a reduction in inflammatory cytokine levels. In vivo efficacy studies are conducted in animal models of infection (e.g., mouse peritonitis or skin infection models). Nisin Z is administered topically or systemically. Bacterial load in tissues is quantified, and survival rates are monitored. For anti-inflammatory studies, animal models of inflammation (e.g., carrageenan-induced paw edema) are used. |
| ADME/Pharmacokinetics |
Nisin Z is a peptide with a molecular weight of approximately 3331 Da. It is soluble in 0.1 M HCl (20 mg/mL) and water (10 mg/mL). It has poor solubility in DMSO (2 mg/mL). It is stored at -20°C under nitrogen, protected from moisture and light. Detailed PK data is not available.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of Nisin Z are not extensively reported. As a naturally occurring lantibiotic used in food preservation, it is generally recognized as safe (GRAS). At high concentrations, it may cause cytotoxicity, but this is typically assessed in parallel with antimicrobial activity in cell-based assays.
|
| References |
|
| Additional Infomation |
Nisin Z is a research-grade antimicrobial peptide. It is widely used in food preservation research and as a tool to study bacterial membrane dynamics. It is not approved for therapeutic use in humans. Its molecular formula is C141H229N41O38S7 and its molecular weight is 3331.1 g/mol.
|
| Molecular Formula |
C141H229N41O38S7
|
|---|---|
| Molecular Weight |
3331.05
|
| Exact Mass |
3329.532
|
| CAS # |
137061-46-2
|
| PubChem CID |
155489899
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.40±0.1 g/cm3(Predicted)
|
| Boiling Point |
2962.5±65.0 °C(Predicted)
|
| LogP |
-7.3
|
| Hydrogen Bond Donor Count |
41
|
| Hydrogen Bond Acceptor Count |
50
|
| Rotatable Bond Count |
67
|
| Heavy Atom Count |
227
|
| Complexity |
7810
|
| Defined Atom Stereocenter Count |
35
|
| SMILES |
CC[C@H](C)[C@H]1C(=O)NC(=C)C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(=O)N1)NC(=O)/C(=C/C)/NC(=O)[C@H]([C@@H](C)CC)N)C(=O)N[C@@H]2[C@@H](SC[C@H](NC(=O)CNC(=O)[C@@H]3CCCN3C2=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]4[C@@H](SC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC4=O)C)CC(C)C)CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]5[C@@H](SC[C@H]6C(=O)N[C@H](C(=O)N[C@@H](CS[C@H]([C@H](C(=O)N6)NC(=O)[C@@H](NC5=O)C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](C(C)C)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(=O)O)CC(=O)N)C)C)C)CC(C)C
|
| InChi Key |
PWFSAVZKCGCNRK-RDLXCTAXSA-N
|
| InChi Code |
InChI=1S/C141H229N41O38S7/c1-24-67(11)103(147)133(211)159-79(27-4)116(194)171-91-57-223-58-92(172-121(199)86(48-65(7)8)166-113(191)72(16)155-136(214)105(68(12)25-2)177-130(91)208)131(209)181-110-77(21)227-60-93(157-102(188)55-150-132(210)97-38-34-44-182(97)140(110)218)126(204)161-81(36-29-32-42-143)118(196)179-107-74(18)224-59-94(158-101(187)54-149-115(193)82(39-45-221-22)162-120(198)85(47-64(5)6)165-111(189)70(14)153-100(186)53-151-134(107)212)127(205)167-88(50-98(145)184)122(200)163-83(40-46-222-23)117(195)160-80(35-28-31-41-142)119(197)180-108-75(19)226-62-96-128(206)168-89(51-99(146)185)123(201)173-95(61-225-76(20)109(139(217)174-96)178-114(192)73(17)156-138(108)216)129(207)170-90(56-183)125(203)176-106(69(13)26-3)137(215)169-87(49-78-52-148-63-152-78)124(202)175-104(66(9)10)135(213)154-71(15)112(190)164-84(141(219)220)37-30-33-43-144/h27,52,63-70,73-77,80-97,103-110,183H,15-16,24-26,28-51,53-62,142-144,147H2,1-14,17-23H3,(H2,145,184)(H2,146,185)(H,148,152)(H,149,193)(H,150,210)(H,151,212)(H,153,186)(H,154,213)(H,155,214)(H,156,216)(H,157,188)(H,158,187)(H,159,211)(H,160,195)(H,161,204)(H,162,198)(H,163,200)(H,164,190)(H,165,189)(H,166,191)(H,167,205)(H,168,206)(H,169,215)(H,170,207)(H,171,194)(H,172,199)(H,173,201)(H,174,217)(H,175,202)(H,176,203)(H,177,208)(H,178,192)(H,179,196)(H,180,197)(H,181,209)(H,219,220)/b79-27-/t67-,68-,69-,70-,73-,74-,75-,76-,77-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92-,93-,94-,95-,96-,97-,103-,104-,105-,106-,107+,108+,109+,110+/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(1S,4S,7S,8S,11R,14S,17R,20S)-7-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(3R,9S,12S,15S,21S,22S)-21-[[(2S)-6-amino-2-[[(3S,4S,7R,13S)-3-[[(3R,6S,12S,15S)-15-[[(Z)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]but-2-enoyl]amino]-12-[(2S)-butan-2-yl]-9-methylidene-6-(2-methylpropyl)-5,8,11,14-tetraoxo-1-thia-4,7,10,13-tetrazacyclohexadecane-3-carbonyl]amino]-4-methyl-2,9,12-trioxo-5-thia-1,8,11-triazabicyclo[11.3.0]hexadecane-7-carbonyl]amino]hexanoyl]amino]-15,22-dimethyl-12-(2-methylpropyl)-9-(2-methylsulfanylethyl)-5,8,11,14,17,20-hexaoxo-1-thia-4,7,10,13,16,19-hexazacyclodocosane-3-carbonyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-14-(2-amino-2-oxoethyl)-4,8,20-trimethyl-3,6,12,15,21-pentaoxo-9,19-dithia-2,5,13,16,22-pentazabicyclo[9.9.2]docosane-17-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoyl]amino]prop-2-enoylamino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~10 mg/mL (~3.00 mM)
DMSO : ~2 mg/mL (~0.60 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.2 mg/mL (0.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 0.2 mg/mL (0.06 mM) (saturation unknown) in 10% DMSO + 90% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.14 mg/mL (0.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3002 mL | 1.5010 mL | 3.0021 mL | |
| 5 mM | 0.0600 mL | 0.3002 mL | 0.6004 mL | |
| 10 mM | 0.0300 mL | 0.1501 mL | 0.3002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
